Artemotil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Artemotil
Accession Number
DB13851
Type
Small Molecule
Groups
Approved
Description

Artemotil (INN; also known as β-arteether), is a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases. It is a semi-synthetic derivative of artemisinin, a natural product of the Chinese plant Artemisia annua.

Structure
Thumb
Synonyms
  • Arteether
  • beta-Arteether
  • beta-Dihydroartemisinin ethyl ether
  • Dihydroartemisinin ethyl ether
External IDs
SM 227
Categories
UNII
XGL7GFB9YI
CAS number
75887-54-6
Weight
Average: 312.406
Monoisotopic: 312.193674002
Chemical Formula
C17H28O5
InChI Key
NLYNIRQVMRLPIQ-XQLAAWPRSA-N
InChI
InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
IUPAC Name
(1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Artemotil.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Artemotil.Approved
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Artemotil.Approved, Vet Approved
AmodiaquineThe serum concentration of Artemotil can be decreased when it is combined with Amodiaquine.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Artemether.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Artemotil.Investigational
ChloroquineThe serum concentration of Artemotil can be decreased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Artemotil.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Artemotil.Approved, Investigational, Vet Approved
DapsoneThe risk or severity of adverse effects can be increased when Artemotil is combined with Dapsone.Approved, Investigational
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Artemotil.Approved
HydroxychloroquineThe serum concentration of Artemotil can be decreased when it is combined with Hydroxychloroquine.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Lumefantrine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Artemotil.Approved, Investigational
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Artemotil.Approved, Investigational
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Artemotil.Approved, Investigational
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Artemotil.Approved, Investigational, Withdrawn
PerazineThe serum concentration of Perazine can be increased when it is combined with Artemotil.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Artemotil.Approved
PrimaquineThe serum concentration of Artemotil can be decreased when it is combined with Primaquine.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Artemotil.Approved, Vet Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Artemotil.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Artemotil.Approved, Investigational
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Artemotil.Approved, Investigational
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Artemotil.Vet Approved
TafenoquineThe serum concentration of Artemotil can be decreased when it is combined with Tafenoquine.Investigational
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Artemotil.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Artemotil.Withdrawn
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Artemotil.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Artemotil.Approved, Withdrawn
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Artemotil.Approved, Investigational
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Artemotil.Approved, Vet Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemotil.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
2272064
BindingDB
50426305
ChEBI
135335
ChEMBL
CHEMBL301267
Wikipedia
Artemotil
ATC Codes
P01BE04 — Artemotil

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.276 mg/mLALOGPS
logP3.52ALOGPS
logP3.84ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.15 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity79.41 m3·mol-1ChemAxon
Polarizability34.08 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:49 / Updated on July 02, 2018 19:57